News | 29 July 2026
Eris Lifesciences posts 13% revenue growth in Q1 FY27; PAT rises 14.5%
As the company's domestic branded formulations business grows 14%, GLP-1 brand Sundae emerges as market leader by prescriptions
As the company's domestic branded formulations business grows 14%, GLP-1 brand Sundae emerges as market leader by prescriptions
Efficient conclusion to the Talc Litigation that eliminates expense associated with litigating remaining roughly 76,000 ovarian Talc claims
Regulated Markets business surges 42%, EBITDA rises 87% as company expands US portfolio and manufacturing capacity
Revenue from operations climbs to Rs. 653.2 crore as pharmaceutical major posts healthy profit growth in the June quarter
The company said it expects the approval to provide LYTENAVA with 12 years of Reference Product Exclusivity under the Biologics Price Competition and Innovation Act
Initiative aims to facilitate 2.5 lakh screenings through 8,500 camps; over 5,000 doctors support first phase of 1.5 lakh screenings
Susvimo is designed to provide continuous drug release into the vitreous through Roche’s Contivue implant
The CHMP’s positive opinion was supported by data from KALOS and LOGOS
State's Pharma Park at Nava Raipur gains momentum as policy reforms and ease-of-doing-business initiatives drive investor confidence
The investment of Rs. 110 crore made in Biodeal during 2024 has now been fully redeemed, delivering returns above the Fund’s expectations
Sculptra uses a unique formulation to stimulate the body’s own collagen production, helping rebuild the skin’s underlying structure and address collagen loss associated with ageing
The successful inspection marks another regulatory milestone for the company's analytical operations, reinforcing its commitment to quality, regulatory compliance, and data integrity across its global analytical network
The two-day debut event is expected to attract more than 2,500 attendees, 120 exhibitors, and participants from over 40 countries
The milestone represents a first regulatory achievement for Asymchem’s DH2 carbapenem site
Diagnostic major expands profit and strategic footprint
EBITDA rises 39%, adjusted PAT jumps 72%; biologics CDMO business expands with new global biosimilar customer
Royalty-free agreement covers supply of generic HIV prevention drug to 129 low- and middle-income countries, subject to regulatory approvals
Transaction moves closer to completion, pending regulatory approvals and other customary closing conditions
Life sciences giant posts USD 11.99 billion in quarterly revenue, beats analyst estimates and lifts full-year revenue and profit guidance
CDMO business drives record growth
Subscribe To Our Newsletter & Stay Updated
